[{"orgOrder":0,"company":"Sensorion","sponsor":"Institut Pasteur","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Institut Pasteur","highestDevelopmentStatusID":"4","companyTruncated":"Sensorion \/ Institut Pasteur"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Sensorion and Institut Pasteur are developing gene therapies, including SENS-501 for otoferlin-related deafness and GJB2-GT for GJB2 mutation-related hearing loss.

                          Product Name : OTOF-GT

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 01, 2024

                          Lead Product(s) : OTOF-GT

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Preclinical

                          Sponsor : Institut Pasteur

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SENS-501 is an adeno-associated vector-based gene therapy for the autosomal recessive non-syndromic Deafness 9. It is being investigated in preclinical stage for DFNB9.

                          Product Name : OTOF-GT

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 02, 2023

                          Lead Product(s) : OTOF-GT

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : OTOF-GT is targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

                          Product Name : SENS-501

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 10, 2022

                          Lead Product(s) : OTOF-GT

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : In vivo experiments conducted safely in non-human primates show promising preliminary data on inner ear tissue tropism and the achievement of a high transduction rate efficiency post Otoferlin Gene Therapy.

                          Product Name : SENS-501

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 06, 2020

                          Lead Product(s) : OTOF-GT

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank